MXPA04001034A - Compuestos para sanar heridas y en contra de envejecimiento. - Google Patents

Compuestos para sanar heridas y en contra de envejecimiento.

Info

Publication number
MXPA04001034A
MXPA04001034A MXPA04001034A MXPA04001034A MXPA04001034A MX PA04001034 A MXPA04001034 A MX PA04001034A MX PA04001034 A MXPA04001034 A MX PA04001034A MX PA04001034 A MXPA04001034 A MX PA04001034A MX PA04001034 A MXPA04001034 A MX PA04001034A
Authority
MX
Mexico
Prior art keywords
inhibitors
aging
wound healing
development
matrix metalloproteinases
Prior art date
Application number
MXPA04001034A
Other languages
English (en)
Inventor
Malik Sohail
Original Assignee
Kimberly Clark Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/032,376 external-priority patent/US7186693B2/en
Application filed by Kimberly Clark Co filed Critical Kimberly Clark Co
Publication of MXPA04001034A publication Critical patent/MXPA04001034A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

La invencion proporciona inhibidores de metaloproteinaseas de matriz que son utiles para alentar el desarrollo de una piel saludable y para tratar las heridas. Los inhibidores son peptidos que tienen secuencias relacionadas a las regiones de desdoblamiento de las formas de proenzima de metaloproteinaseas de matriz. Los inhibidores de peptido de la invencion pueden ser formulados en composiciones terapeuticas, lociones, cremas, vendajes para heridas y coberturas de la piel que facilitan la curacion y el desarrollo de piel saludable, desalientan las cicatrices y las arrugas y mejoran los efectos de la curacion.
MXPA04001034A 2001-08-16 2002-08-15 Compuestos para sanar heridas y en contra de envejecimiento. MXPA04001034A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31272601P 2001-08-16 2001-08-16
US10/032,376 US7186693B2 (en) 2001-08-16 2001-12-21 Metalloproteinase inhibitors for wound healing
US10/153,185 US6906036B2 (en) 2001-08-16 2002-05-21 Anti-aging and wound healing compounds
PCT/US2002/026198 WO2003016520A1 (en) 2001-08-16 2002-08-15 Anti-aging and wound healing compounds

Publications (1)

Publication Number Publication Date
MXPA04001034A true MXPA04001034A (es) 2004-05-27

Family

ID=46150134

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04001034A MXPA04001034A (es) 2001-08-16 2002-08-15 Compuestos para sanar heridas y en contra de envejecimiento.
MXPA04001033A MXPA04001033A (es) 2001-08-16 2002-08-15 Compuesto de sanado para heridas y anti-cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA04001033A MXPA04001033A (es) 2001-08-16 2002-08-15 Compuesto de sanado para heridas y anti-cancer.

Country Status (9)

Country Link
US (2) US6906036B2 (es)
EP (2) EP1423515A4 (es)
KR (4) KR100944318B1 (es)
CN (2) CN1549722A (es)
AU (1) AU2002324737A1 (es)
BR (1) BR0211641A (es)
CA (2) CA2456158A1 (es)
MX (2) MXPA04001034A (es)
WO (2) WO2003016520A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071164B2 (en) * 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) * 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7094754B2 (en) * 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7517857B2 (en) * 2002-01-29 2009-04-14 Posco Immune-modulating peptide
WO2004011043A1 (en) * 2002-07-31 2004-02-05 University Of Florida Antimicrobial and antiproteolytic wound dressing
GB0224986D0 (en) 2002-10-28 2002-12-04 Smith & Nephew Apparatus
US7148194B2 (en) * 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) * 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
EP1648493B1 (en) * 2003-07-07 2009-12-09 Van Andel Research Institute Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
GB0518804D0 (en) * 2005-09-15 2005-10-26 Smith & Nephew Exudialysis tissue cleanser
US8758313B2 (en) 2003-10-28 2014-06-24 Smith & Nephew Plc Apparatus and method for wound cleansing with actives
GB0325126D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with heat
US11298453B2 (en) 2003-10-28 2022-04-12 Smith & Nephew Plc Apparatus and method for wound cleansing with actives
GB0325120D0 (en) * 2003-10-28 2003-12-03 Smith & Nephew Apparatus with actives
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
US8062272B2 (en) 2004-05-21 2011-11-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
US7909805B2 (en) 2004-04-05 2011-03-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
US10058642B2 (en) 2004-04-05 2018-08-28 Bluesky Medical Group Incorporated Reduced pressure treatment system
US10413644B2 (en) 2004-04-27 2019-09-17 Smith & Nephew Plc Wound treatment apparatus and method
US8529548B2 (en) 2004-04-27 2013-09-10 Smith & Nephew Plc Wound treatment apparatus and method
GB0409446D0 (en) 2004-04-28 2004-06-02 Smith & Nephew Apparatus
US7753894B2 (en) 2004-04-27 2010-07-13 Smith & Nephew Plc Wound cleansing apparatus with stress
WO2007027849A2 (en) * 2005-08-31 2007-03-08 Board Of Regents, The University Of Texas System Multiribbon nanocellulose as a matrix for wound healing
PT1806358E (pt) * 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
US7645583B2 (en) * 2005-12-14 2010-01-12 Kimberly-Clark Worldwide, Inc. Identification of compounds for inhibiting complexation of C-reactive protein with fibronectin
US20070264354A1 (en) * 2006-05-09 2007-11-15 Herman Richard M Treatment of a wound with a vasodilator
WO2009012449A1 (en) 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Temporal release of growth factors from 3d micro rod scaffolds for tissue regeneration
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
ES2330291B1 (es) * 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
WO2011044443A2 (en) 2009-10-09 2011-04-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Matricryptic ecm peptides for tissue reconstruction
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
ES2561814T3 (es) * 2010-09-17 2016-03-01 Abbell Ab Tratamiento de infecciones micóticas
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP2934555B1 (en) 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
EP3677291B1 (en) 2013-05-10 2024-01-03 Smith & Nephew PLC Fluidic connector for irrigation and aspiration of wounds
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
CN106163530A (zh) 2013-12-09 2016-11-23 小利兰·斯坦福大学托管委员会 用于治疗衰老相关病症的方法和组合物
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
KR101744959B1 (ko) 2014-12-05 2017-06-12 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
KR20200115683A (ko) 2015-02-05 2020-10-07 무하메드 마제에드 올레아노일 펩티드 조성물 및 콜라겐 증진
JP6921006B2 (ja) 2015-06-15 2021-08-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化関連症状を治療するための方法および組成物
SG11201906198PA (en) 2017-01-27 2019-08-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
KR102007078B1 (ko) 2017-03-24 2019-08-05 (주)셀아이콘랩 콜라겐 생성을 촉진시키는 신규한 헵타펩타이드 단량체 및 이량체를 포함하는 피부 노화 방지를 위한 화장품 조성물
EP3703636A1 (en) * 2017-11-03 2020-09-09 Systagenix Wound Management, Limited Nutrient-enriched dressing
KR102087044B1 (ko) * 2018-04-30 2020-03-10 인하대학교 산학협력단 Mmp-10 또는 이를 코딩하는 유전자의 발현을 억제하는 제제를 포함하는 암 전이 억제용 조성물
CZ308845B6 (cs) * 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran
CN111632127B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物及其于皮肤保护的用途
CN111748041B (zh) * 2019-03-11 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 微环境控释型功能化水凝胶、其制备方法及应用
CN113307851B (zh) * 2021-06-11 2022-04-29 珠海医美企业管理有限公司 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用
CN113698452B (zh) * 2021-08-23 2023-08-18 四川丽妍工坊生物科技有限公司 一种促皮肤修复肽、制备方法及其应用
WO2023080578A1 (ko) * 2021-11-05 2023-05-11 주식회사 레메디 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2507379A1 (fr) 1981-06-05 1982-12-10 Europ Composants Electron Bloc de condensateurs en serie et multiplicateur de tension utilisant un tel bloc de condensateurs
US5280106A (en) 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
US5270447A (en) 1988-05-20 1993-12-14 The United States Of America As Represented By The Department Of Health & Human Services Metalloproteinase peptides: role in diagnosis and therapy
US5698671A (en) 1989-03-21 1997-12-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metalloproteinase peptides
JPH0734014B2 (ja) 1990-01-26 1995-04-12 アメリカ合衆国 コラーゲナーゼを定量的に測定するための方法
EP1262493A1 (en) 1992-10-29 2002-12-04 Bayer Corporation Diagnostic assay for latent matrix metalloproteinase no. 9
JP3098640B2 (ja) 1992-12-24 2000-10-16 富士薬品工業株式会社 ヒト７２−ｋＤａゼラチナーゼ／ＩＶ型コラゲナーゼの免疫学的定量法
JP2673929B2 (ja) 1993-04-12 1997-11-05 富士薬品工業株式会社 ヒト間質型コラゲナーゼと阻害剤との複合体の免疫学的定量法および臨床診断への応用
US6150152A (en) 1993-05-28 2000-11-21 Washington University Human macrophage metalloelastase
WO1995002045A2 (en) * 1993-07-09 1995-01-19 Celltech Limited Gelatinase antagonists used for treating cancer
JPH07303482A (ja) 1993-11-30 1995-11-21 Fuji Yakuhin Kogyo Kk 新規なメタロプロテアーゼおよびそれをコードするｄｎａ
JPH07159402A (ja) 1993-12-09 1995-06-23 Kyodo Nyugyo Kk Ｉｖ型コラゲナ−ゼ測定法
JPH07330795A (ja) * 1994-06-07 1995-12-19 Toagosei Co Ltd ペプチドおよびモノクローナル抗体
ATE226642T1 (de) 1994-07-07 2002-11-15 Tno Modifizierte proenzyme als substrate für proteolische enzyme
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
JPH08136548A (ja) 1994-11-11 1996-05-31 Morinaga & Co Ltd 泌尿器癌の診断法
JPH08134098A (ja) 1994-11-11 1996-05-28 Morinaga & Co Ltd ヒトｔｉｍｐ−１の高感度測定法
EP0815202B1 (en) 1994-12-13 2007-02-21 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
JP2949467B2 (ja) 1995-02-16 1999-09-13 富士薬品工業株式会社 免疫学的測定法によるヒトプロマトリックスメタロプロテアーゼ７の定量
US5770691A (en) 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis
EP0870826A4 (en) 1995-07-14 2002-05-02 Daiichi Fine Chem Co Ltd NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
JPH0984589A (ja) 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk 新規なタンパク質
JPH0987299A (ja) 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk Ｍｍｐ−２活性化因子に特異的なモノクローナル抗体
IT1277904B1 (it) 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
EP1019528B1 (en) 1996-01-04 2003-10-29 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for assaying proteolytic enzymes using fluorescence-quenched substrates
JPH09206099A (ja) 1996-01-31 1997-08-12 Sekisui Chem Co Ltd 細胞機能測定方法
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US6022948A (en) 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
DE69732784T2 (de) * 1996-12-06 2006-04-06 Fonden Til Fremme Af Eksperimental Cancerforskning Inhibierung von invasiver remodulierung
US6046031A (en) 1997-01-21 2000-04-04 Human Genome Sciences, Inc. Metalloproteinases
JPH10210982A (ja) 1997-01-31 1998-08-11 Fuji Yakuhin Kogyo Kk 新規なタンパク質
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
EP0972071A4 (en) 1997-03-07 2004-04-21 Tropix Inc TEST ARRANGEMENT FOR PROTEAS INHIBITORS
WO1998040475A1 (en) 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
AUPO573697A0 (en) 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
JPH10287700A (ja) 1997-04-10 1998-10-27 Fuji Yakuhin Kogyo Kk 活性型マトリライシン（ｍｍｐ−７）に対する抗体及びそれを用いた免疫学的測定法
JPH10313896A (ja) 1997-05-15 1998-12-02 Yamanouchi Pharmaceut Co Ltd マトリックスメタロプロテアーゼに対する発色団又は蛍光団を有する新規な活性測定用合成基質
US6043087A (en) 1997-07-25 2000-03-28 The New York Blood Center Monospecific antibody reactive with matrix metalloproteinase cleavage products of fibrin(ogen)
DE69837516T2 (de) 1997-11-14 2007-12-27 Murata Mfg. Co., Ltd., Nagaokakyo Vielschichtkondensator
EP1040196A2 (en) 1997-12-19 2000-10-04 American Home Products Corporation Transgenic animal model for degenerative diseases of cartilage
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer
WO1999058126A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
AU4571099A (en) * 1998-06-16 2000-01-05 General Hospital Corporation, The Matrix metalloproteinase proenzyme activator
US6191225B1 (en) 1998-08-31 2001-02-20 Ppg Industries Ohio, Inc. Thermosetting compositions containing carboxylic acid functional polymers and epoxy functional polymers prepared by atom transfer radical polymerization
AU6511199A (en) 1998-10-08 2000-04-26 Calbiochem Novabiochem Corporation Diagnostic assay for matrix metalloproteinase 9 and use thereof
EP1783140A3 (en) * 1998-10-16 2007-07-11 Otsuka Pharmaceutical Co., Ltd. Neovascular-specific peptides
USH1973H1 (en) 1998-10-22 2001-07-03 Novartis Ag Human neutrophil collagenase splice variant
CA2364503A1 (en) * 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
JP2000270874A (ja) 1999-03-25 2000-10-03 Fuji Chemical Industries Ltd 新規な膜結合型メタロプロテアーゼ
US6274717B1 (en) 1999-04-20 2001-08-14 Smithkline Beecham Corporation Splicing variant of human membrane-type matrix metalloproteinease-5 (MT-MMP5-L)
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
JP2001072589A (ja) * 1999-07-06 2001-03-21 Toagosei Co Ltd 制癌剤
KR100509119B1 (ko) * 1999-07-16 2005-08-18 주식회사 엘지생활건강 프로시아니딘 올리고머를 유효성분으로 하는 약제
US6403637B1 (en) 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
CA2383562A1 (en) * 1999-08-26 2001-03-01 Keith M. Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
GB9927576D0 (en) 1999-11-23 2000-01-19 Univ Birmingham Novel assay
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
GB0004531D0 (en) 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7094754B2 (en) * 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds

Also Published As

Publication number Publication date
KR100944318B1 (ko) 2010-03-03
AU2002324737A1 (en) 2003-03-10
BR0211641A (pt) 2004-07-13
MXPA04001033A (es) 2004-05-27
WO2003018748A3 (en) 2004-05-27
EP1513542A2 (en) 2005-03-16
US20050239710A1 (en) 2005-10-27
WO2003016520A1 (en) 2003-02-27
EP1423515A1 (en) 2004-06-02
CN1543503B (zh) 2011-06-15
US7196162B2 (en) 2007-03-27
CA2456158A1 (en) 2003-02-27
WO2003018748A2 (en) 2003-03-06
KR100996047B1 (ko) 2010-11-22
EP1513542A4 (en) 2009-07-15
KR20100018107A (ko) 2010-02-16
CA2455883A1 (en) 2003-03-06
KR20040028974A (ko) 2004-04-03
EP1423515A4 (en) 2008-02-27
CN1543503A (zh) 2004-11-03
US6906036B2 (en) 2005-06-14
KR20090051781A (ko) 2009-05-22
CN1549722A (zh) 2004-11-24
KR20040023708A (ko) 2004-03-18
US20030148959A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
MXPA04001034A (es) Compuestos para sanar heridas y en contra de envejecimiento.
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
CY1108633T1 (el) Κοσμητικη συνθεση βασεως σουκραλφατ και θειικων αλατων χαλκου και ψευδαργυρου
TW200501976A (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
HUP0300135A3 (en) Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails
ATE438618T1 (de) Inhibitoren von humanem adam-10
IL166016A0 (en) Topical treatment of skin diseases
UA88175C2 (ru) Способ косметической обработки стареющей кожи при помощи местного применения композиции, которая содержит циклогексанмоно-, -ди- или -триолы или циклогексилметан- или -этан-, или -пропанолы
EP1578780A4 (en) PROCESS FOR INCREASING FIBRONECTIN
MXPA03011622A (es) Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas.
AU2002231087A1 (en) Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
AU2003270625A8 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
IL138594A0 (en) Use of protease inhibitors for treating skin wounds
GB0217136D0 (en) Wound healing & treatment of fibrosis
YU31104A (sh) Inhibicija virusa n-dokozanolom
AU3934000A (en) Inhibitors of endothelin-1 synthesis
YU76403A (sh) Sintetski peptidi i postupak za preventivnu i terapeutsku upotrebu kod širenja kancera i metastaza
AU2001292818A1 (en) Use of transcription factors for treating inflammation and other diseases
AU2001291604A1 (en) Use of proton pump inhibitors for treating diseases of the locomotor system
BR0314364A (pt) Uso de inibidores de pde iv para tratar angiogênese
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
AU2002224905A1 (en) Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing processes
AU2002257740A1 (en) Use of aprotinin for treating wounds and inflammation
ITMO20020173A0 (it) Medicamento adesivo per l'emostasi di ferite
UA40081A (uk) Спосіб лікування гіперплазії лімфоїдної тканини носоглотки

Legal Events

Date Code Title Description
FG Grant or registration